A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503)
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503)
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 109, Issue 4, Pages 943-949
Publisher
Springer Nature
Online
2013-07-19
DOI
10.1038/bjc.2013.380
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Implications of Plasma Protein Binding for Pharmacokinetics and Pharmacodynamics of the -Secretase Inhibitor RO4929097
- (2012) J. Wu et al. CLINICAL CANCER RESEARCH
- Cediranib monotherapy in patients with advanced renal cell carcinoma: Results of a randomised phase II study
- (2012) Peter Mulders et al. EUROPEAN JOURNAL OF CANCER
- Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II)
- (2012) Paulo M. Hoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III)
- (2012) Hans-Joachim Schmoll et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of RO4929097, a Gamma Secretase Inhibitor of Notch Signaling, in Patients With Refractory Metastatic or Locally Advanced Solid Tumors
- (2012) Anthony W. Tolcher et al. JOURNAL OF CLINICAL ONCOLOGY
- Cediranib in patients with malignant mesothelioma: A phase II trial of the University of Chicago Phase II Consortium
- (2012) Nicholas P. Campbell et al. LUNG CANCER
- Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGF–VEGFR2 signalling
- (2012) Rui Benedito et al. NATURE
- DLL4-Notch Signaling Mediates Tumor Resistance to Anti-VEGF Therapy In Vivo
- (2011) J.-L. Li et al. CANCER RESEARCH
- Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours
- (2011) Tanja Trarbach et al. INVESTIGATIONAL NEW DRUGS
- Association of High Levels of Jagged-1 and Notch-1 Expression with Poor Prognosis in Head and Neck Cancer
- (2010) Jen-Tsun Lin et al. ANNALS OF SURGICAL ONCOLOGY
- Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours
- (2010) Hester van Cruijsen et al. EUROPEAN JOURNAL OF CANCER
- High Jagged1 Expression Predicts Poor Outcome in Clear Cell Renal Cell Carcinoma
- (2010) Kerong Wu et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma
- (2010) Tracy T. Batchelor et al. JOURNAL OF CLINICAL ONCOLOGY
- Expression of delta-like ligand 4 (Dll4) and markers of hypoxia in colon cancer
- (2009) A M Jubb et al. BRITISH JOURNAL OF CANCER
- Preclinical Profile of a Potent -Secretase Inhibitor Targeting Notch Signaling with In vivo Efficacy and Pharmacodynamic Properties
- (2009) L. Luistro et al. CANCER RESEARCH
- A Notch updated
- (2009) An-Chi Tien et al. JOURNAL OF CELL BIOLOGY
- Randomized, Double-Blind Trial of Carboplatin and Paclitaxel With Either Daily Oral Cediranib or Placebo in Advanced Non–Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 Study
- (2009) Glenwood D. Goss et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group
- (2008) Glenwood Goss et al. EUROPEAN JOURNAL OF CANCER
- Determination of intact oxaliplatin in human plasma using high performance liquid chromatography-tandem mass spectrometry
- (2008) Wenjiang Zhang et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- Rational targeting of Notch signaling in cancer
- (2008) P Rizzo et al. ONCOGENE
- Notch signaling regulates tumor angiogenesis by diverse mechanisms
- (2008) J Dufraine et al. ONCOGENE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started